Cancer Drug Lapatinib Offers Safer HER2 Route for Patients With Failing Hearts
A new clinical case report shows that the oral HER2 inhibitor lapatinib, with its short half-life and low cardiac toxicity, ...
A new clinical case report shows that the oral HER2 inhibitor lapatinib, with its short half-life and low cardiac toxicity, ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine